| abstract |
The invention encompasses restricted bicyclic and tricyclic CGRP receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for use in the therapy for the treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, menopausal suffocations, inflammatory diseases of the airways, such as asthma and chronic obstructive pulmonary disease (COPD), and other treatment conditions of which can be effected by antagonism of CGRP receptors. (see formula (I) and (II)). |